A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II/III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs AL 335/odalasvir/simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 28 Nov 2017 This study has been completed in Germany as per European Clinical Trials Database.
- 06 Nov 2017 Planned number of patients changed from 250 to 54.
- 06 Nov 2017 Planned primary completion date changed from 6 Dec 2021 to 30 Oct 2020.